Develop and manufacture advanced scientific instruments for molecular and materials research. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 9% a year over the last 4 years. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 2.3× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 71% of them.
No analyst target is on record for this company.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
Growth: Sales growth trails the sector average.
The stock trades 16% below its peak. The market has trimmed its expectations for the company.
The company sells $3.4B a year; the problem isn’t sales — it’s costs running above that number.
It pays out $15.63 per share each year — regular cash for whoever holds the stock.
A loss of $8.6M against $3.4B in annual sales.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 18/100.
The growth engine is running at low revs right now. Report-card grade: 22/100.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.